MKI67 and mucinous adenocarcinoma: For this reason, these chemotherapeutic agents function most effectively in active, proliferative tumors, whereas slow-growing, low-Ki-67 LI tumors, such as clear cell adenocarcinoma and mucinous adenocarcinoma, do not respond well, and treatment with these therapies may result in hyposensitivity.